XNPT 7.68 Xenoport Inc $XNPT Hit a 52 week high of 7.72

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
XNPT 7.68 Xenoport Inc $XNPT Hit a 52 week high of 7.72 Closing the day 09:44 at 7.68 -0.03 -0.39% With a day low of 7.58 and a total volume of 19,196.

XNPT Recent Posts: http://investorshangout.com/XenoPort-Inc-XNPT-55935/

XNPT Xenoport Inc Recent Headline News

XenoPort's (XNPT) CEO Ron Barrett Presents at Credit Suisse Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - 28 mins ago

XNPT: 7.88 (+0.17)

Can the Uptrend Continue for XenoPort (XNPT)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 6:33AM CST
Can the Uptrend Continue for XenoPort (XNPT)?
XNPT: 7.88 (+0.17)

XenoPort to Present at the Credit Suisse Healthcare Conference
Business Wire - Thu Nov 06, 12:09PM CST
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2014 Credit Suisse Healthcare Conference in Phoenix, Arizona. The live presentation will occur at 8:30 a.m. Pacific Time (9:30 a.m. Mountain Time) on Wednesday, November 12, 2014. A replay of the presentation will also be available.
XNPT: 7.88 (+0.17)

XenoPort Has Returned 39.6% Since SmarTrend Recommendation (XNPT)
Comtex SmarTrend(R) - Wed Nov 05, 11:04AM CST
SmarTrend identified an Uptrend for XenoPort (NASDAQ:XNPT) on August 26th, 2014 at $5.17. In approximately 2 months, XenoPort has returned 39.59% as of today's recent price of $7.21.
XNPT: 7.88 (+0.17)

XenoPort's (XNPT) CEO Ron Barrett on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 9:40PM CST

XNPT: 7.88 (+0.17)

XenoPort (XNPT) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Nov 04, 3:55PM CST

XNPT: 7.88 (+0.17)

XenoPort beats by $0.49, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:27PM CST

XNPT: 7.88 (+0.17)

XenoPort Reports Third Quarter Financial Results
Business Wire - Tue Nov 04, 3:07PM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today financial results for the third quarter and nine months ended September 30, 2014. Revenues for the third quarter were $31.1 million compared to $2.5 million for the same period in 2013. Revenues for the third quarter included $25.0 million in collaboration revenue resulting from XenoPort's license agreement with Reckitt Benckiser Pharmaceuticals, Inc. Net income for the third quarter was $8.3 million compared to a net loss of $18.8 million for the same period in 2013. At September 30, 2014, XenoPort had cash, cash equivalents and short-term investments of $113.4 million.
XNPT: 7.88 (+0.17)

XNPT, AMRS, GSAT, CRDC, IOSP, OKS Expected To Be Down After Next Earnings Releases
M2 - Mon Nov 03, 3:33AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Tuesday, November 4th 2014 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and December earnings reports. Xenoport Inc (NASDAQ:XNPT), AMYRIS INC (NASDAQ:AMRS), Globalstar Inc (OTC:GSAT), Cardica Inc (NASDAQ:CRDC), INNOSPEC INC. (NASDAQ:IOSP), ONEOK PARTNERS, L.P. (NYSE:OKS) are all expected to be Down After their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down After earnings are released Tuesday:
AMRS: 2.89 (+0.06), IOSP: 44.22 (+0.33), OKE: 56.56 (+0.31), CRDC: 0.86 (-0.01), OKS: 48.17 (+0.67), GSAT: 2.72 (+0.12), XNPT: 7.88 (+0.17)

XenoPort Up 32.4% Since SmarTrend Uptrend Call (XNPT)
Comtex SmarTrend(R) - Wed Oct 29, 9:38AM CDT
SmarTrend identified an Uptrend for XenoPort (NASDAQ:XNPT) on August 26th, 2014 at $5.17. In approximately 2 months, XenoPort has returned 32.43% as of today's recent price of $6.84.
XNPT: 7.88 (+0.17)

XenoPort reports November 4
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 10:53AM CDT

XNPT: 7.88 (+0.17)

XenoPort to Release Third Quarter Financial Results on November 4
Business Wire - Thu Oct 23, 9:00AM CDT
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its third quarter financial results on November 4, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day to provide a summary of its financial results and general business updates. A replay of the call will be available for one week following the event.
XNPT: 7.88 (+0.17)

XenoPort Shares Up 22.6% Since SmarTrend's Buy Recommendation (XNPT)
Comtex SmarTrend(R) - Wed Oct 22, 9:18AM CDT
SmarTrend identified an Uptrend for XenoPort (NASDAQ:XNPT) on August 26th, 2014 at $5.17. In approximately 2 months, XenoPort has returned 22.56% as of today's recent price of $6.33.
XNPT: 7.88 (+0.17)

Uptrend Call Working As XenoPort Stock Rises 20.2% (XNPT)
Comtex SmarTrend(R) - Tue Oct 14, 5:17PM CDT
SmarTrend identified an Uptrend for XenoPort (NASDAQ:XNPT) on August 26th, 2014 at $5.17. In approximately 2 months, XenoPort has returned 20.23% as of today's recent price of $6.21.
XNPT: 7.88 (+0.17)

Commit To Buy XenoPort At $5, Earn 15.8% Annualized Using Options
StockOptionsChannel.com - Thu Oct 09, 10:29AM CDT
Investors eyeing a purchase of XenoPort Inc shares, but tentative about paying the going market price of $5.82/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
XNPT: 7.88 (+0.17)

Anacor Pharmaceuticals Appoints Wendell Wierenga to Its Board of Directors
Business Wire - Fri Sep 12, 7:30AM CDT
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that its Board of Directors has appointed Wendell Wierenga, Ph.D. to serve as a Class III director until the Company's 2016 annual meeting of shareholders. Anacor also announced that Paul Klingenstein has resigned from the Board.
CYTK: 4.30 (-0.09), SNTS: (), OCRX: 5.59 (+0.06), ANAC: 31.58 (+0.30), XNPT: 7.88 (+0.17)

Xenoport/NIAAA Collaborate on Alcoholism Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:55PM CDT
Xenoport, Inc. (XNPT) entered into a clinical trial collaboration agreement with the National Institute on Alcohol Abuse and Alcoholism, for a study that will evaluate HORIZANT as a potential treatment for alcohol use disorder (AUD).
CBPO: 68.75 (+2.47), CBM: 23.88 (+0.37), AMGN: 161.93 (-0.49), XNPT: 7.88 (+0.17)

XenoPort to Present Data for Novel Fumarate Analog XP23829 at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston
Business Wire - Wed Sep 10, 7:30AM CDT
XenoPort, Inc. (Nasdaq:XNPT) announced today that it will present data on XP23829, an investigational prodrug of monomethyl fumarate (MMF), at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston. Data being presented include the results from a clinical trial evaluating the safety, tolerability and pharmacokinetics of XP23829.
XNPT: 7.88 (+0.17)

XenoPort and the NIAAA Announce Clinical Trial Agreement to Study HORIZANT as a Potential Treatment for Alcohol Use Disorder
Business Wire - Tue Sep 09, 7:30AM CDT
XenoPort, Inc. (Nasdaq:XNPT) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA) announced today that they have entered into an agreement to conduct a clinical trial of HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets as a potential treatment for alcohol use disorder (AUD). Under the terms of the agreement, XenoPort will supply clinical trial material and the NIAAA will conduct and pay all other expenses associated with the proposed clinical trial of HORIZANT. XenoPort will have access to study results generated under the proposed clinical trial to support potential regulatory filings for HORIZANT.
XNPT: 7.88 (+0.17)

DTSI, XNPT, ZUMZ, BIDU, DISCA, KBE Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Sep 04, 9:30AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of DTS, INC. (NASDAQ TSI), Xenoport Inc (NASDAQ:XNPT), Zumiez Inc (NASDAQ:ZUMZ), Baidu Inc (NASDAQ:BIDU), Discovery Communications Inc (NASDAQ ISCA), Kbw Bank Etf (NYSE:KBE) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
ZUMZ: 35.63 (+1.69), DTSI: 33.50 (+0.21), KBE: 33.86 (+0.34), BIDU: 249.87 (-0.47), DISCA: 31.79 (-0.20), XNPT: 7.88 (+0.17)

XenoPort Inc (XNPT) Stock Research Links

XNPT Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Event Industry Power 50 Voting Surge Ahead of Close

Updated Category News Views 12

An Unexpected Wave of Enthusiasm in Event Industry The Event Industry Power 50 is getting some serious action this year. Over 3,500 votes have already rolled in, smashing last year's numbers with days still left on the clock. It seems like folks can't wait to see their favorite event powerhouses crowned at this year's gala, which kicks off October 27 in New York City....

Continue Reading
Dan Brown Joins Guidewire: Big Moves in P&C Software

Updated Category News Views 14

Turning the Insurance World on Its Head Just when you think the enterprise software scene is getting predictable, along comes a bit of news to shake things up. Guidewire, a name known in the P&C insurance software world, has roped in a veteran—Dan Brown—who's got more than a quarter-century under his belt shaping product strategies. It’s not just another suit...

Continue Reading
OMLYCLO Shakes Up U.S. Biologic Market as Key Player

Updated Category News Views 14

Ah, the pharmaceutical game is shifting again, and this time Celltrion USA's putting their chips down with OMLYCLO, the shiny new omalizumab biosimilar. Here we see a product that's not just approved but interchangeable with XOLAIR, making it a front-runner in the allergic and inflammatory conditions battleground. If you're a patient or a provider navigating these murky...

Continue Reading
GL1F Crypto: A Breakthrough in On-Chain AI for Crypto

Updated Category News Views 8

The Dawn of On-Chain Machine Learning In a world where crypto folks often tout decentralization like it’s the holy grail, GenesisL1 is throwing open the doors to a new kind of crypto playground with GL1F Crypto. A decentralized on-chain AI studio? Sounds like sci-fi, but here we are—hands on the precipice of democratized machine learning in your browser. A Lab in...

Continue Reading
Travelers Turn to Direct Booking Amid Cost Surge

Updated Category News Views 18

Getting Ahead of the Travel Expense Game Rising fees and tighter budgets haven't persuaded holiday travelers to abandon their plans. Instead, they’re sharpening their axes, looking for clearer paths to their vacation goals without slicing off an arm and a leg. With the cost of travel climbing faster than a runaway elevator, folks are getting smart about where their...

Continue Reading
Hiromi Asai's Akatsuki Shines at Paris Fashion Week

Updated Category News Views 11

An Ode to Tradition Amid Modern Menswear From the bustling avenues of New York to the storied streets of Paris, Hiromi Asai is showcasing something that strikes a chord deep in the fashion industry's soul. Her Spring/Summer 2027 collection, "Akatsuki — Before the Dawn," takes its rare blend of age-old Japanese textile craftsmanship across the pond to the City of Light....

Continue Reading
Hilarity and Hassles in NYC Co-op Life Exposed in New Book

Updated Category News Views 15

Co-op Living: Not All It's Cracked Up to Be Let me tell you something, buying a co-op in New York City isn't just signing on the dotted line and moving in. Nope, it's a whole damn production. Jeff Namian's book, Thin Walls/Thick Ears, lays it all out with a mix of humor and hard truths, painting a stark picture of NYC co-op living. He's not just telling his own story of...

Continue Reading
TRIMAX Poised to Meet AI-Driven Power Challenges

Updated Category News Views 11

TRIMAX's Bold Move into AI-Powered Infrastructure It feels like we're standing on the cusp of a seismic shift, folks. Artificial intelligence isn't just another buzzword anymore—it's a juggernaut reshaping our digital world. TRIMAX Power Systems is gearing up to ride this wave, with its eyes set on capturing a chunk of the booming demand for fast-deployable power...

Continue Reading
ProClad Unveils Innovative Hybrid 2.0 Cookware

Updated Category News Views 13

Revolutionizing Cookware: The Launch of Hybrid 2.0 Today, everyone's buzzing about ProClad's big reveal—the Hybrid 2.0 Pan. Now, before you roll those skeptical eyes, hear me out. This isn’t your average bit of kitchen fluff; it’s a heavyweight contender stepping into the everyday cooking ring. What they've done here is combine the muscle of stainless steel searing...

Continue Reading
Metropolitan Dermatology's Strategic Expansion into Barnegat

Updated Category News Views 13

Diving into Barnegat's Dermatology Landscape Metropolitan Dermatology has taken a strategic step by opening a new location right in the heart of Barnegat, New Jersey. Talk about a win-win for the folks in Ocean County. This isn't just another clinic opening up shop; it's about bringing comprehensive medical and surgical dermatologic care straight to the people who need...

Continue Reading

Top 5 Most Recently Viewed Articles

Matachewan's Strategic Steps for Shareholder Value Enhancement

Updated Category News Views 117

Matachewan's Commitment to Shareholder Value Matachewan Consolidated Mines, Limited (TSXV: MCM) is taking significant steps to enhance shareholder value. This initiative follows a thorough evaluation by the Company Board of Directors, focusing on the potential to distribute cash and other assets to shareholders. This decision underscores Matachewan's commitment to its...

Continue Reading
BJ’s Charitable Foundation Grants Over $1 Million to Local Heroes

Updated Category News Views 105

BJ’s Charitable Foundation Awards Significant Community Grants BJ’s Wholesale Club Inc. (NYSE: BJ) has impactful news as the company announces it has awarded over $1 million in community grants aimed at assisting local organizations dedicated to vital causes. This funding addresses various needs, from combatting hunger to supporting cancer patients and athletes with...

Continue Reading
Vista Energy Expands Market Presence with PEPASA Acquisition

Updated Category News Views 322

Vista Energy's Strategic Move in the Oil Sector Vista Energy, S.A.B. de C.V. (NYSE: VIST), has expanded its portfolio by acquiring Petronas E&P Argentina S.A. This strategic acquisition marks a significant step in Vista's ambition to enhance its operational scale in the energy-rich Vaca Muerta region. The deal, valued at approximately US$ 900 million plus equity, provides...

Continue Reading
ModivCare Investors Face Class Action Lawsuit Amid Losses

Updated Category News Views 107

Understanding the Class Action Lawsuit Against ModivCare Investors who have faced losses as a result of their investment in ModivCare, Inc. should take immediate notice of an important class action lawsuit. This notice serves as a reminder for affected individuals to consider their options and the potential implications of this legal action. ModivCare, recognized under...

Continue Reading
Exploring the Growth of the CSTD Market: Opportunities Ahead

Updated Category News Views 133

Understanding the CSTD Market Dynamics The Closed System Drug Transfer Device (CSTD) market is witnessing an impressive transformation, with a significant valuation jump projected over the next decade. A recent report released by Allied Market Research outlines the market's current status and its promising future landscape, indicating an escalation to $3.6 billion by 2033...

Continue Reading